CAPTRUST Financial Advisors
AUTL

CAPTRUST Financial Advisors’s Autolus Therapeutics AUTL Stock Holding History

CAPTRUST Financial Advisors’s Portfolio AUTL Stock Details AUTL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-500
Closed -$1K – 2222
2022
Q2 		$1K Hold
500
– – ﹤0.01% 4626
2022
Q1 		$2K Buy
+500
New +$2.1K ﹤0.01% 4457
2021
Q3 		– Sell
-160
Closed -$1K – 4638
2021
Q2 		$1K Buy
+160
New +$993 ﹤0.01% 4304

Other funds holding AUTL

Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return
SP
Syncona Portfolio St Peter Port, Guernsey $25.7M AUM 13.32% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $3.89B AUM 201.1% 1-Year Est. Return
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Schroder Investment Management Group
Schroder Investment Management Group London, United Kingdom $122B AUM 29.27% 1-Year Est. Return
PG
Pendal Group Sydney, Australia $11.6B AUM 12.87% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return

CAPTRUST Financial Advisors's AUTL Position: Q3 2022 in Review

CAPTRUST Financial Advisors sold out of Autolus Therapeutics (AUTL) in Q3 2022, closing a stake of 500 shares — an estimated $1K sold.

CAPTRUST Financial Advisors first reported a position in AUTL in Q2 2021 and held it in 3 quarters. The position peaked at $2K in Q1 2022. 66 funds tracked by Wall St. Rank hold AUTL as of Q3 2022.

  • CAPTRUST Financial Advisors reported no remaining Autolus Therapeutics position as of Q3 2022 after selling out during the quarter.
  • CAPTRUST Financial Advisors sold 500 Autolus Therapeutics shares in Q3 2022, an estimated $1K.
  • CAPTRUST Financial Advisors first reported a position in Autolus Therapeutics in Q2 2021 and held it in 3 quarters.
  • CAPTRUST Financial Advisors's Autolus Therapeutics position peaked at $2K in Q1 2022.
  • 66 funds tracked by Wall St. Rank held Autolus Therapeutics as of Q3 2022.

Based on CAPTRUST Financial Advisors's 13F filing for Q3 2022, filed 16 Nov 2022.